Phase 4
Completed N=200
Ciprofloxacin for Prevention of BK Infection
BK Virus Infection
Source: ClinicalTrials.gov NCT01789203 ↗
Enrolled (actual)
200
Serious AEs
26.5%
Results posted
Nov 2019
Primary outcomePrimary: Number of Patients Developing BK Infection at 6 Months Post-transplant — 25; 5 Participants
◆ Published Evidence
Established
23citations · ~3 / year
Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial.
Summary
BK infection is an important cause of graft dysfunction and graft loss after renal transplantation. It has been widely accepted that emergence of BK virus correlates with the more potent immunosuppressive agents used to lower acute rejection rates. In contrast to other opportunistic infections after transplantation, for which routine prophylactic agents are administered, there is no effective agent for the prevention of BK infection. Some data, however, suggests that quinolone antibiotics such as ciprofloxacin may have activity against BK virus. This has led us to investigate whether routine, short-term ciprofloxacin administration post-transplant can lower the incidence of BK infection.
Linked Publications (2)
-
Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial.
-
Interventions for BK virus infection in kidney transplant recipients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients Developing BK Infection at 6 Months Post-transplant |
25; 5 | — |
| SECONDARY Number of Patients With Gram Negative Urinary Tract Infections at 6 Months |
17; 14 | — |
| SECONDARY Number of Patients With Bacteremia at 6 Months |
3; 2 | — |
| SECONDARY Number of Patients With Quinolone-resistant Infection at 6 Months |
15; 7 | — |
| SECONDARY Clostridium Difficile at 6 Months |
1; 0 | — |
| SECONDARY Serious Adverse Events |
35; 18 | — |
| SECONDARY Time to BK Infection |
90; 76.5 | — |
| SECONDARY BK Viremia at 1 Year |
31; 8 | — |
| SECONDARY First Plasma Viral Loads |
2514; 1423 | — |
| SECONDARY Acute Rejection at 1 Year |
14; 7 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female subjects over the age of 18 years
- Recipients of a primary or repeat renal allograft either alone (from a deceased or living donor) or as a dual-kidney transplant
- Signed informed consent form prior to any research assessment
Exclusion Criteria
- Patients with known severe allergy to ciprofloxacin
- History of tendon rupture or tendinitis
- Use of antiarrythmic drugs known to prolong the QT interval such as class IA antiarrhythmic drugs (e.g. quinidine, procainamide, disopyramide), class III antiarrhythmic drugs (e.g. amiodarone, sotalol)
- Patients with history of previous non-renal transplantation
- Recipients administered rituximab within one year prior to transplantation, or recipients expected to receive rituximab as part of desensitization strategy or for the presence of historical donor specific antibodies
- QTc interval interval of greater than 500 msec on admission or post-operative EKG
- BK nephropathy with previous transplant
- BK viremia on admission
- Any condition present during the initial transplant hospitalization that in the investigator's judgment would increase the risk associated with participation in the study
Data sourced from ClinicalTrials.gov (NCT01789203) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.